Abstract Number: 2090 • 2016 ACR/ARHP Annual Meeting
Investigating the Genetic Variations of Antiphospholipid Syndrome By High-Throughput Exome Sequencing
Background/Purpose: The antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence of antiphospholipid antibodies in serum together with clinical manifestations such as thrombosis,…Abstract Number: 2092 • 2016 ACR/ARHP Annual Meeting
Plasma Soluble Triggering Receptor Expressed on Myeloid Cells-1 Is Elevated in Patients with Thrombotic Primary Antiphospholipid Syndrome.
Background/Purpose : Primary antiphospholipid syndrome (PAPS) is characterized by thrombotic and/or obstetrical morbidity in the presence of persistent antiphospholipid antibodies (APLA) and in the absence…Abstract Number: 2094 • 2016 ACR/ARHP Annual Meeting
Complement Activation in Antiphospholipid Syndrome Due to the Multi-Activated Pathways of the Complement System
Background/Purpose: Complement activation is proposed as one of the major thrombophilic mechanisms in antiphospholipid syndrome (APS). Among three complement pathways (classical, alternative and lectin), activation…Abstract Number: 2095 • 2016 ACR/ARHP Annual Meeting
Autoantibodies Against High Density Lipoprotein-Associated Proteins Are Related to Elevated Oxidized Low Density Lipoprotein Levels in Antiphospholipid Syndrome
Background/Purpose: Oxidized low-density lipoprotein (oxLDL), a key molecule in atherogenesis, serves as the source of anionic charged particles that bind to beta2glycoprotein I (Β2GPI) and…Abstract Number: 77 • 2016 ACR/ARHP Annual Meeting
Integrated Analysis of Microrna and mRNA Expression Profiles Related to Cardiovascular Disease in Monocytes from Systemic Lupus Erythematosus and Primary Antiphospholipid Syndrome Patients
Background/Purpose: The interplay between miRNAs and their mRNA targets might constitute an important mechanism in the regulation of the proatherothrombotic status of SLE and APS…Abstract Number: 2099 • 2016 ACR/ARHP Annual Meeting
Micrornas As Potential Modulators of Atherothrombosis in Antiphospholipid Syndrome
Background/Purpose: 1) To identify and characterize microRNAs linked to thrombosis and atherosclerosis development in APS; 2) To assess the effects of antiphospholipid antibodies in that…Abstract Number: 920 • 2016 ACR/ARHP Annual Meeting
Autoantigen-Specific T Cell and Antibody Reactivity to a Human Gut Commensal in Antiphospholipid Syndrome
Autoantigen-specific T Cell and Antibody Reactivity to a Human Gut Commensal in Antiphospholipid Syndrome William Ruff1, Carina Dehner1, Alex Roth1, Silvio M. Vieira1, Cassyanne L.…Abstract Number: 2875 • 2016 ACR/ARHP Annual Meeting
Depressed Serum IgM Levels in SLE Are Restricted to Defined Subgroups
Background/Purpose: Natural IgM autoantibodies have been proposed to have protective properties, and decreased levels of IgM to phosphorylcholine (PC) in SLE are associated with higher…Abstract Number: 2174 • 2015 ACR/ARHP Annual Meeting
Neutrophils in Primary Antiphospholipid Syndrome Are Characterized By a Prominent Activated Phenotype and Uniquely Remodeled Chromatin Architecture
Background/Purpose: Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by recurrent thrombotic events, pregnancy complications, and the presence of antiphospholipid antibodies. The pathogenesis of…Abstract Number: 2175 • 2015 ACR/ARHP Annual Meeting
Comparative Study Between Coagucheck XS Versus Standard Laboratory Practice Protrombine Time for Monitoring Anticoagulant Therapy in Patients with Antiphospholipid Syndrome
Background/Purpose: Antiphospholipid Syndrome (APS) is an autoimmune disease characterized by antiphospholipid antibodies (aPL) associated with thrombosis and/or pregnancy morbidity. Although initially described in patients with systemic lupus erythematosus (SLE) it…Abstract Number: 2178 • 2015 ACR/ARHP Annual Meeting
Oxidation of beta2-Glycoprotein I (beta2-GPI) Associates with the Presence of Antibodies to Domain I of beta2-GPI in Patients with the Antiphospholipid Syndrome but Is Not Affected By the Antibodies in Vivo in a Rat Model
Background/Purpose: β2GPI represents the major antigenic target for antiphospholipid antibodies (aPL), the hallmark of antiphospholipid syndrome (APS). β2GPI contains five homologous domains, with domain I…Abstract Number: 2180 • 2015 ACR/ARHP Annual Meeting
Primary Antiphospholipid Syndrome Patients Display Increased Levels of Cell-Bound C4d in Comparison to SLE and Healthy Donors
Background/Purpose: Systemic Lupus Erythematosus (SLE) patients display high levels of the cell-bound complement activation factor C4d deposits on erythrocytes, B lymphocytes and platelets. In particular,…Abstract Number: 2183 • 2015 ACR/ARHP Annual Meeting
Clinical and Epidemiological Correlates of the Adjusted Global Anti-Phospholipid Syndrome Score in a Large Cohort of Chinese APS Patients
Background/Purpose: It is well known that anti-phospholipid antibodies (aPL) are associated with an increased risk of arterial and venous thrombosis and pregnancy loss/morbidity. However, anticoagulation…Abstract Number: 2184 • 2015 ACR/ARHP Annual Meeting
Non-Criteria Clinical Manifestations in Antiphospholipid Syndrome: Clinical Behavior and Association with Damage Accrual
Background/Purpose: The relevance of non-criteria clinical manifestations of antiphospholipid syndrome (APS) has been less studied than its thrombotic and obstetric features. The aim of this…Abstract Number: 2186 • 2015 ACR/ARHP Annual Meeting
The Role of Hydroxychloroquine Treatment on Pregnancy Outcome in Women with Antiphospholipid Antibodies
Background/Purpose: With good management, around 70% of pregnant women with Antiphospholipid Syndrome (APS) will deliver a viable live infant.However, current management does not prevent all…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- 19
- Next Page »